Bendamustine: increased mortality observed when used in non-approved combination treatments or outside the approved indications

This direct healthcare professional communication includes further detail on the safety concern. Fatal toxicities were mainly (opportunistic) infections, but some fatal cardiac, neurological, and respiratory toxicities were also reported. The SPC is being revised.

Seacross Pharmaceuticals